Generated by AI
Vistagen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric and neurological disorders. The company develops intranasal product candidates known as pherines, designed to act through nose-to-brain neurocircuitry and support rapid, targeted delivery within the central nervous system. Its current pipeline centers on treatments for conditions such as social anxiety disorder, major depressive disorder, and menopause-related vasomotor symptoms. Vistagen Therapeutics Inc. also pursues research and development using human neuroscience and clinical testing to advance non-systemic therapeutic approaches. Headquartered in South San Francisco, California, the company operates in the biotechnology sector and works to address unmet needs across mental health and women’s health markets.
Website343 Allerton Avenue
South San Francisco, CA, 94080
United States
The latest articles about VTGN.
Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibilitySOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported fina
Summary of Sep 28's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Summary of Aug 10's posts. Generated by AI.
Summary of Sep 24's posts. Generated by AI.
Investors talking about VTGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.